Latest News
- Psoriasis
Tuesday, October 09, 2018
Online Care May Be As Effective as In-Person Care for Psoriasis
Teledermatology may be as effective as seeing a doctor in person when it comes to improving the symptoms of psoriasis, according to a new study in JAMA Network Open. “Patients with chronic sk…
Read the full storyMonday, October 08, 2018
Ortho Dermatologics Receives Tentative FDA Approval for Bryhali for Plaque Psoriasis
The FDA has provided tentative approval of the New Drug Application for Bryhali (halobetasol propionate) Lotion, 0.01%, for the topical treatment of plaque psoriasis in adult patients. Bryhali Lotion …
Read the full story
Friday, October 05, 2018
EPI Acquires Rights to Cloderm Cream from Promius Pharma
EPI Health has acquired the rights rights to Cloderm® (clocortolone pivalate) Cream, 0.1% and its authorized generic from Promius Pharma, LLC, a wholly owned subsidiary of D…
Read the full storyTuesday, October 02, 2018
Ortho Dermatologics’ Bryhali Lotions Performs Well in Two Phase 3 Psoriasis Trials
Two Phase 3 randomized controlled trials show that Bryhali (halobetasol propionate) Lotion, 0.01%, an investigational potent to superpotent corticosteroid in the treatment of moderate-to-severe p…
Read the full story
Monday, September 17, 2018
UCB: Study Data for Cimzia and Bimekizumab Presented at EADV
UCB has presented new findings on Cimzia® (certolizumab pegol) and one of its key pipeline molecules, bimekizumab, for the treatment of moderate-to-severe chronic plaque psoriasis (PSO), along wit…
Read the full story
Monday, September 17, 2018
Almirall and Evotec Form Dermatology Research Collaboration
Alrimal and Evotec aim to discover and develop first-in-class therapeutics through a novel approach to disrupt cell signaling, that is expected to deliver highly potent and durable treatments for debi…
Read the full story
Tuesday, September 04, 2018
AbbVie to Present New Data at 27th EADV Congress
AbbVie will present new data across investigational medicines and Humira® (adalimumab) at the 27th European Academy of Dermatology and Venereology (EADV) Congress, September 12…
Read the full story
Thursday, August 30, 2018
Psoriasis Myths, Stigmas Abound
Stigmatizing views and myths about psoriasis are pervasive among the general population and medical students in the United States, according to multidisciplinary research from the Perelman School of M…
Read the full storyWednesday, August 29, 2018
FDA Accepts Ortho Derm's Resubmission of NDA for Duobrii Lotion for Plaque Psoriasis
The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application (NDA) for Duobrii (halobetasol propionate and tazarotene) (IDP-118) Lotion for the topical treatment of plaque psoriasis.…
Read the full story
Thursday, August 23, 2018
Lupin Launches Generic Clobetasol Cream in the US
Lupin has launched its Clobetasol Propionate Cream 0.05%, having received approval from the FDA earlier. Lupin's Clobetasol Propionate Cream USP 0.05% is the generic equivalent of Fougera Pharmac…
Read the full storyTuesday, August 21, 2018
Report: Psoriasis in America in 2018
Recently released psoriasis survey results reveal that only 10 percent of patients feel their condition is under control with their current treatment plans; meanwhile, their symptoms -- and the mental…
Read the full story
Tuesday, August 21, 2018
MC2 Therapeutics Reports Positive Topline Data for Investigational Topical for Psoriasis
MC2-01 Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) from MC2 Therapeutics A/S achieved its primary and secondary endpoints, according to recently reported top-line data from…
Read the full story
Thursday, August 16, 2018
Ortho Dermatologics Resubmits NDA for Duobrii Lotion
Ortho Dermatologics, a division of Bausch Health Companies Inc., has resubmitted a New Drug Application (NDA) to the FDA for Duobrii™ (halobetasol propionate and tazarotene; …
Read the full story
Tuesday, August 14, 2018
Burt’s Bees Nature-Based Sensitive Skin Care Outperforms MD-Recommended Regimen
Burt’s Bees nature-based sensitive skin regimen is well-tolerated as well as clinically and statistically superior to a leading dermatologist-recommended synthetic regimen, according to a s…
Read the full storyMonday, August 13, 2018
Escalier Biosciences’ Doses First PsO Patient with ESR-114; Announces Clinical Advisory Board
The first patient has been dosed in a Phase 1/2a study evaluating Escalier Biosciences’ ESR-114 topical gel for mild-to-moderate psoriasis. "The initiation of this study represents a sig…
Read the full story
